Statin-induced low cholesterol is not associated with poor outcome in chronic heart failure

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 17, Issue 3, 2012, Pages 284-290

  Silva, Sérgio ^a   Lourenço, Patrícia ^a   Paulo, Cristiana ^a   Ferreira, Ester ^a   Lebreiro, Ana ^a   Sousa, Alexandra ^a   Mascaranhas, Joana ^a   Patacho, Marta ^a   Araujo, Jose Paulo ^a   Bettencourt, Paulo ^a  

^a University of Porto   (Portugal)

Author keywords

cholesterol; heart failure; prognosis; statins

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; AMBULATORY CARE; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DEATH; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT OUTCOME;

AGED; CHEMICAL HAZARD RELEASE; CHOLESTEROL; CHRONIC DISEASE; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84865116073     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248411429967     Document Type: Article

References (20)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival study (4 S). Lancet. 1994 ; 344 (8934). 1383-1389
2. Sheperd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary prevention Study Group. N Engl J Med. 1995 ; 333 (20). 1301-1307
3. Ramasubbu K, Estep J, White DL, Deswal A, Mann DL. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol. 2008 ; 51 (4). 415-426
4. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet. 1996 ; 348 (9034). 1079-1082 (Pubitemid 26343606)
5. Wolfrum S, Liao JK Statins: understanding clinical use. Saunders. Metha JL, ed. 2004: 163-187.
6. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. 2004 ; 43 (4). 642-648 (Pubitemid 38229538)
7. Anker SD, Clark AL, Winkler R, et al. Statin use and survival in patients with chronic heart failure-results from two observational studies with 5200 patients. Int J Cardiol. 2006 ; 112 (2). 234-242 (Pubitemid 44376681)
8. Kjekshus J, Apetrei E, Barrios V, et al. CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med.. 2007 ; 357 (22). 2248-2261 (Pubitemid 350190755)
9. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 ; 372 (9645). 1231-1239
10. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J AM Coll Cardiol. 2004 ; 43 (8). 1439-1444 (Pubitemid 38496352)
11. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail. 2002 ; 8 (4). 216-224
12. Swedberg K, Cleland J, Dargie H, et al. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J.. 2005 ; 26 (11). 1115-11140
13. Harst P, Voors A, Gilst W, Böhm M, Veldhuisen D. Statins in treatment of chronic heart failure: biological and clinical considerations. Cardiovascular Research. 2006 ; 71 (3). 443-454 (Pubitemid 44107859)
14. Sola S, Mir MQ, Rajagopalan S, Helmy T, Tandon N, Khan B. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Card Fail. 2005 ; 11: 607-612 (Pubitemid 41463732)
15. Rauchhaus M, Coats AJS, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet. 2000 ; 356: 930-933
16. De Pinieux G. Lipid-lowering drugs and mitochondrial functions: effects of HMG-Coa reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol. 1996 ; 42 (3). 333-337 (Pubitemid 26284422)
17. Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet. 2004 ; 363: 892-894 (Pubitemid 38368841)
18. Vredevoe DL, Woo MA, Doering LV, Brecht ML, Hamilton MA, Fonarow GC. Skin test anergy in advance heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1998 ; 82: 323-328 (Pubitemid 28364248)
19. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 ; 287: 3215-3222 (Pubitemid 34686102)
20. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol. 2004 ; 93: 1124-1129 (Pubitemid 38521041)